DataMEDS AI delays Q2 2026 10-Q filing

DataMEDS AI, Inc. filed a Notification of Late Filing indicating it will not submit its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 by the original due date of August 14, 2026.

Rhea-AI Filing Summary

DataMEDS AI, Inc. filed a Notification of Late Filing indicating it will not submit its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 by the original due date of August 14, 2026. The company states the report cannot be completed on time without unreasonable effort or expense and that it needs additional time to finalize the preparation and review of its financial statements and related disclosures. DataMEDS AI, Inc. expects to file the Form 10-Q within the five-calendar-day extension period permitted under Rule 12b-25 of the Securities Exchange Act of 1934.

Key Figures

Quarter end date: June 30, 2026 Original Form 10-Q due date: August 14, 2026 Extension length: five-calendar-day extension period

3 metrics

Quarter end date June 30, 2026 Quarterly period covered by the delayed Form 10-Q

Original Form 10-Q due date August 14, 2026 Prescribed due date for the Q2 2026 Form 10-Q

Extension length five-calendar-day extension period Additional time permitted for filing the Form 10-Q under Rule 12b-25

Key Terms

Rule 12b-25, Form 10-Q, Notification of Late Filing, Securities Exchange Act of 1934

4 terms

Rule 12b-25 regulatory

"expects to file the Form 10-Q within the five-calendar-day extension period pursuant to Rule 12b-25"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-Q regulatory

"Quarterly Report on Form 10-Q for the quarter ended June 30, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

Notification of Late Filing regulatory

"is filing this Notification of Late Filing on Form 12b-25"

A notification of late filing is a formal public statement that a company failed to submit a required regulatory report (for example, quarterly or annual financial statements) by the deadline. It matters to investors because missed filings can signal accounting, operational, or governance problems, may lead to fines or trading restrictions, and increases uncertainty about the company's transparency—like a public “we missed the deadline” flag that raises risk for shareholders.

Securities Exchange Act of 1934 regulatory

"extension period pursuant to Rule 12b-25 of the Securities Exchange Act of 1934"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did DataMEDS AI, Inc. (MEDS) file an NT 10-Q?

DataMEDS AI, Inc. filed an NT 10-Q because it determined its Form 10-Q could not be completed on time without unreasonable effort or expense. The company needs additional time to finish preparing and reviewing its financial statements and related disclosures for the quarter ended June 30, 2026.

Which period does DataMEDS AI, Inc. (MEDS) NT 10-Q relate to?

The NT 10-Q from DataMEDS AI, Inc. relates to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. This report covers the company’s operating and financial results for that quarter, which it has not yet been able to finalize and file.

When was the DataMEDS AI, Inc. (MEDS) Form 10-Q originally due?

The Form 10-Q for DataMEDS AI, Inc. was originally due on August 14, 2026. Because it could not meet this prescribed due date, the company submitted a Notification of Late Filing under Rule 12b-25 to obtain a short extension for that quarterly report.

When does DataMEDS AI, Inc. (MEDS) expect to file its delayed Form 10-Q?

DataMEDS AI, Inc. expects to file its Form 10-Q within the five-calendar-day extension period allowed for a late Form 10-Q under Rule 12b-25. The company indicates it will use this brief extension to complete preparation and review of its quarterly financial statements and disclosures.

Who signed the DataMEDS AI, Inc. (MEDS) NT 10-Q notification?

The Notification of Late Filing for DataMEDS AI, Inc. was signed by Eric Sherb, the company’s Chief Financial Officer, dated August 14, 2026. His contact telephone number is also provided as the point of contact regarding this late-filing notification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 04:15 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 12b-25

Commission File Number: 001-42530

NOTIFICATION OF LATE FILING

☐ Form 10-K	☐ Form 20-F	☐ Form 11-K	☒ Form 10-Q
☐ Form 10-D	☐ Form N-SAR	☐ Form N-CSR

For Period Ended: June 30, 2026

☐ Transition Report on Form 10-K	☐ Transition Report on Form 10-Q
☐ Transition Report on Form 20-F	☐ Transition Report on Form N-SAR
☐ Transition Report on Form 11-K

For the Transition Period Ended: _______________________________________

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________

PART I

REGISTRANT INFORMATION

Full name of registrant	DataMEDS AI, Inc.
Former name if applicable
Address of principal executive office	3000 Bayport Drive, Suite 950
City, state and zip code	Tampa, FL 33607

PART II

RULE 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III

NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

DataMEDS AI, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (the “Form 10-Q”), which is due on August 14, 2026. The Company has determined that the Form 10-Q cannot be filed within the prescribed time period without unreasonable effort or expense. The Company requires additional time to complete the preparation and review of its financial statements and related disclosures to be included in the Form 10-Q. The Company expects to file the Form 10-Q within the five-calendar-day extension period pursuant to Rule 12b-25 of the Securities Exchange Act of 1934.

PART IV

OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Eric Sherb		(843)		302-1785
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes ☒ No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

-2-

DataMEDS AI, Inc.

(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: August 14, 2026		/s/ Eric Sherb
	By:	Eric Sherb
	Title:	Chief Financial Officer

-3-